HHS/DoJ WOULD ISSUE "ADVISORY OPINIONS" ON LEGALITY OF SUPPLIER-PROVIDER DEALS UNDER INSURANCE REFORM MEASURE; RISK-SHARING PROTECTION ALSO INCLUDED
This article was originally published in The Gray Sheet
Executive SummaryHealth care-suppliers and providers could receive federal "advisory opinions" on the legality of their business arrangements under an anti-fraud provision in the health insurance reform legislation (HR 3103) reported out of a House/Senate conference committee July 31. The bill was adopted by the House on Aug. 1, followed by the Senate on Aug. 2.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.